Objective: To assess the effect the therapeutic effect of CTHepaB capsules on nude mice carrying human hepatocellular carcinoma cells (HCC) infected with hepatitis B virus (HBV). Method: Nude mice after HCC transplant Hep3B infected with HBV on the right thigh, appeared a tumor on the thigh on the 14th day of transplantation, had an average size of 74,6 ± 14,3 mm3), randomly divided into 2 groups of 15 rats each and randomly divided into 3 lots (5 mice / lot): in the control group, drink 0.9% NaCl solution; Treatment, oral dose of CTHepaB 0.96g / kg / 24h; Reference batch, oral dose of 5FU 10mg / kg / 24h.Give the rats the drug according to the above division for 4 weeks. Group 1 used to evaluate the effect of research drugs on tumor size, survival / death rate; Average lifetime of the mouse. Group 2, used for splenectomy to evaluate the density of some immune cells and the HBV-DNA quantification of tumor cells. Results: CTHepaB capsules reduced the average tumor size compared to the control group, equivalent to that of the group using 5FU at dose of 10mg/kg/24h; Limiting the death rate of mice at the evaluation points 70, 76, 85, 90 days after taking the drug compared to the control group and on 85, 90 days, compared with the reference group; increases average survival time of mice; Increased number of NK cells, Macrophage cells and DC cells in mouse spleen; Reduces the amount of HBV-DNA in mouse tumor cells. Conclusion: CTHepaB capsule with dose of 0.96g/kg/24h has good therapeutic effect, in nude mice carrying HCC infected with HBV.
Keywords: CTHepaB, hepatocellular carcinoma, hepatitis B virus, hepatitis B
virus-infected hepatocellular carcinoma cell transplant model